Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc (IOVA) Straddle
IOVA straddle scan found 90 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 60.1%.
Read more
Trading a IOVA straddle lets you take a pure volatility position on Iovance Biotherapeutics Inc without committing to a direction. Iovance Biotherapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate IOVA straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on IOVA profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Iovance Biotherapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the IOVA straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc.
has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the IOVA straddle is the cleanest expression of that view. Our scanner prices every IOVA straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a IOVA straddle into a catalyst or short a IOVA straddle to harvest decay, the options straddle setups that matter are all in one place.
| Jan 21, 2028 | 20.00 | $12.63 | 485 | 4% | 60.1% | $32.63 | $7.38 | 0 |
| Jan 15, 2027 | 20.00 | $10.03 | 114 | 4% | 57.5% | $30.03 | $9.98 | 34 |
| Nov 20, 2026 | 17.50 | $7.23 | 58 | 4% | 57.4% | $24.73 | $10.28 | 0 |
| Mar 19, 2027 | 17.50 | $8.35 | 177 | 4% | 57.1% | $25.85 | $9.15 | 0 |
| Mar 19, 2027 | 20.00 | $10.63 | 177 | 4% | 57.0% | $30.63 | $9.38 | 0 |
| Jan 19, 2029 | 20.00 | $15.23 | 849 | 4% | 56.9% | $35.23 | $4.78 | 0 |
| Jan 21, 2028 | 17.50 | $11.15 | 485 | 4% | 55.7% | $28.65 | $6.35 | 50 |
| Dec 18, 2026 | 17.50 | $7.63 | 86 | 4% | 55.5% | $25.13 | $9.88 | 132 |
| Oct 16, 2026 | 12.50 | $2.45 | 23 | 4% | 54.4% | $14.95 | $10.05 | 1 |
| Jan 15, 2027 | 17.00 | $7.63 | 114 | 4% | 53.8% | $24.63 | $9.38 | 1 |
As of September 23, 2026
Find the right straddle before volatility moves
Track IOVA straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→